Revelation completes patient dosing in study of Gemini in CKC - BioTuesdays
Summary
1 Articles
1 Articles
Revelation completes patient dosing in study of Gemini in CKC - BioTuesdays
Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl disaccharide—in patients with stage III and stage IV chronic kidney disease (CKC). According to Revelation, several study data sets are expected during Q3, 2025, including safety standards, changes in hematologic parameters, in vitro…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium